Introduction of Duloxetine hydrochloride and survey of analytical methods

Duloxetine hydrochloride is indicated for the treatment of major depressive disorder (MDD). Its chemical designation is (+)-(S)
The aim of present study was to develop a new analytical method for the determination of related substances and for quantitative estimation of Duloxetine hydrochloride along with in vitro dissolution studies in pharmaceutical dosage forms by liquid chromatography LC to establish inherent stability of Duloxetine through stress studies under a variety of ICH recommended test conditions. In the present study, the additional benefit of in vitro dissolution studies is, Duloxetine degrades rapidly in acidic pH conditions. As per regulatory requirement stability indicating LC methods are required for acidic dissolution mediums. Hence developed UPLC is useful for estimation of drug release in presence of degradation impurities.
Duloxetine has been determined in pharmaceutical preparations by LC [1, 2] , by spectrophotometric [3] and by LCMS [4, 5, 6] Hence a reproducible stability-indicating reverse phase UPLC method was developed for the quantitative determination of Duloxetine hydrochloride and its three impurities. The method was also applied for study of in-vitro dissolution profiles in pharmaceutical dosage forms.
Development of a new analytical method for the determination of related components and assay of Duloxetine hydrochloride in
pharmaceutical dosage forms by UPLC
Materials
Standards of Duloxetine Hydrochloride, Impurity-1, Impurity-2 and Impurity-3, and Duloxetine 60 mg capsules were supplied by Dr. Reddy's laboratories limited, Hyderabad, India. The HPLC grade acetonitrile, methanol, tertahydrofuran and analytical grade KH2PO4 and ortho phosphoric acid were purchased from Merck, Darmstadt, Germany.
Water was prepared by using Millipore MilliQ Plus water purification system.
Equipment
Acquity UPLC TM system (Waters, Milford, USA) we used consists of a binary solvent manager, a sample manager and a photodiode array (PDA)
detector. The output signal was monitored and processed using empower2 software. Cintex digital water bath was used for hydrolysis studies. Photo stability studies were carried out in a photo stability chamber (Sanyo, Leicestershire, UK). Thermal stability studies were performed in a dry air oven (Cintex, Mumbai, India).
Chromatographic Conditions
LC was carried out on a Waters Aquity UPLC with photodiode array detector. The output signal was monitored and processed using 
Sample preparation
A stock solution of Duloxetine hydrochloride (2.0 mg mL -1 ) was prepared by dissolving an appropriate amount of drug in diluent (methanol: water 90:10 (v/v); respectively). Working solutions containing 200 and 20 μg mL -1 were prepared from this stock solution for determination of related substances and for assay determination, respectively. A mixed stock solution (0.5 mg mL -1 ) of the impurities (denoted Impurity-1 to Impurity-3) was also prepared in methanol.
Preparation of tablets sample solution
Duloxetine hydrochloride is a capsule conatins pellets containing 60 mg of Duloxetine. Twenty capsules of Duloxetine (60 mg) were individually weighed to get the average weight of the pellets. An amount of pellets equivalent to 20 mg of Duloxetine was transferred to 100 mL volumetric flask, added 70 mL of methanol: water 90:10, v/v (diluent) sonicated for 20 min and diluted to 100 mL (200 µg mL -1 ). The resulting solution was centrifuged at 3,000 RPM for 15 min (supernatant solution was used for purity evaluation). 10 mL of supernatant solution was transferred and diluted to 100 mL with diluent (20 µg mL -1 ). This solution was filtered using 0.45 µm nylon 66-membrane filter and used for the assay analysis.
Generation of stress samples
One lot of Duloxetine hydrochloride capsules (60 mg) were selected for stress testing. From the ICH Stability guideline: "stress testing has to be carried out on a single lot of material. Different kinds of forced degradation conditions (i.e., heat, humidity, acid, base, oxidative and light) were employed on one lot of Duloxetine capsules based on the guidance available from ICH Stability Guideline (Q1AR2). The details of the stress conditions used are as follows:
a) Acid hydrolysis:
Drug solution in 1N HCl was exposed at 60°C for 3 h.
b) Base hydrolysis:
Drug solution in 1N NaOH was exposed at 60°C for 3 h c) Oxidative stress:
Drug solution in 6% H2O2 was exposed at 30°C temperature for 3 h.
d) Water hydrolysis:
Drug solution in water was exposed at 60°C for 3 h.
e) Thermal stress:
Pellets were subjected to dry heat at 60°C for 10 days.
f) Photolytic degradation:
The photo degradation was carried out by exposing the Duloxetine hydrochloride capsules pellets in solid state to light providing an overall illumination of not less than 1.2 million lux hours and an integrated near ultraviolet energy of not less than 200 W h/m 2 , which took about 10 days period in photo stability chamber.
Method development and optimization of chromatographic conditions
Forced degradation studies were performed to develop a stability indicating UPLC method for the quantitative determination and purity evaluation of Duloxetine hydrochloride capsules. Stressed samples obtained during forced degradation studies including the samples of impurity-1, impurity-2 and impurity-3 were utilized in the UPLC method development.
Selection of wavelength
Impurities and Duloxetine hydrochloride solutions were prepared in diluents and scanned in UPLC PDA detector; all the impurities and Duloxetine are having UV maxima at about 236 nm (Fig: 4.3.F1) . Hence detection at 236 nm was selected for method development purpose. 
Column Selection
The main target of the chromatographic method was to get the separation among impurities namely impurity-1, impurity-2 and impurity-3 and degradation products (mainly at 0.87 RRT) from For Inertsil ODS-3, 50 mm × 2.1 mm, 2μm particles column, impurity-2 was co-eluted with Duloxetine peak and also impurity-3 was eluted as a broad peak. For Waters Aquity BEH C18, 50 x 2.1 mm; 1.7 μm column, impurity-2 was co-eluted with Duloxetine peak and the resolution between Duloxetine and degradation product at 0.87 RRT was poor. For Zorbax XDB C-18, 50 mm x 4.6 mm with 1.8 µm particles column, impurity -1, degradation product at 0.87 RRT, impurity-2 and impurity-3 were well separated from Duloxetine peak, but impurity-3 was strongly retained (RT was at about 29 min). Hence Zorbax XDB C-18, 50 mm x 4.6 mm with 1.8 µm particles column was chosen for further method development. 
Effect of pH
To get better separation of impurities namely impurity-1, impurity-2, impurity-3 and degradation products (mainly the unknown impurity at 0.87 RRT) from Duloxetine and to elute the impurities and Duloxetine as symmetrical peaks, different pH buffers from pH range 4.0 to 7.0 (pH 4.0 and 7.0) was studied. For pH 4.0 study, the mobile phase was "0.01 M KH2PO4 buffer, tetra hydro furan and methanol in the ratio 67: 23: 10 (v/v/v), pH adjusted to 4.0 with ortho phosphoric acid". For pH 7.0 study, the mobile phase was "0.01 M ammonium acetate buffer, tetra hydro furan and methanol in the ratio 67: 23: 10 (v/v/v), pH adjusted to 7.0 with aqueous ammonia solution". For above all pH study column used was Zorbax XDB C-18, 50 mm × 4.6 mm, 1.8 μm and flow rate was 0.6 mL min -1 At pH 7.0, Peak distortion of Duloxetine peak was noticed and coelution of impurity-2 with Duloxetine was observed and also impurity-3 was strogly retained (RT was about 19 min) in the column. At pH 4.0, impurity-1, unknown (0.87 RRT), impurity-2 and Duloxetine peaks are well separated from each other. But impurity-3 was strongly retained (RT was about 29 min). Since impurity-3 was strongly retained when by pH decreased from 7.0 to 4.0, no further reduction in the pH was studied.
Hence pH 4.0 was selected for method pH. To elute impurity-3 faster, elution mode was switched to gradient elution mode from isocratic mode.
Effect of Column Temperature
The effect of column oven temperature was studied from 25° C to 40°C, the symmetry of Duloxetine peak was 1.8 at 25°C. When temperature was increased to 40°C, the symmetry of Duloxetine peak was improved to 1.4. Hence column temperature was chosen at 40°C.
Effect of Organic solvent
When "mixture 0.01 M KH2PO4 buffer, tetra hydro furan and methanol in the ratio 67: 23: 10 (v/v/v), pH adjusted to 4.0 with ortho phosphoric acid" was used as mobile phase (solvent A) in isocratic elution, the compound impurity-3 was strongly retained in the column. Ratio's of methanol and tetrahydrofuran in solvent A were optimized to achieve good resolution between Duloxetine and impurity-2, and between unknown impurity (at RRT 0.87) and Duloxetine peaks.
When methanol was used as a solvent in solvent B (buffer: methanol: 60:40, v/v) instead of acetonitrile, the retention time of impurity-3 was shifted towards higher side (13 min) due to high interactions of impurity-3 with column (lipophilicity). To improve the retention time of impurity-3, the strength of the solvent was increased by replacing methanol with acetonitrile. Different mixtures of buffer and acetonitrile were applied to improve the retention time and symmetry of impurity-3. When 40% acetonitrile was used as a solvent in solvent B retention time of impurity-3 was improved (9.8 min) and symmetry of impurity-3 was also improved. The interference from excipients gelatin, hypromellose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate, sucrose, sugar spheres, talc, titanium dioxide, and triethyl citrate was also checked by injecting sample solutions of excipients. There was no interference found at retention times of impurities (impurity-1, impurity-2 and impurity-3) and Duloxetine peak.
Degradation behavior
UPLC studies on Duloxetine under different stress conditions suggested the following degradation behavior.
Degradation in Acidic solution
Duloxetine underwent degradation in 1N HCl on heating at 60°C for 3 h. Major degradation was observed with formation of impurity-1, impurity-3 and unknown impurity at RRT 0.87 (3.392 RT) (Fig: 4 
Degradation in Basic solution:
When Duloxetine HCl pellets were exposed to 1 N NaOH at 60°C for 3 h, minor degradation was observed with formation of impurity-3 ( 
Oxidative conditions
Duloxetine HCl pellets were exposed to 6% Hydrogen peroxide at 30 ºC for 3 h. Duloxetine has shown no significant sensitivity towards the treatment of Hydrogen peroxide (Fig: 4 
Photolytic conditions
When the drug pellets was exposed to light for an overall illumination 
Thermal Degradation
Duloxetine HCl is stable for heat when drug pellets were exposed to dry heat at 60°C for 10 days (Fig: 4 The unknown impurity (0.87 RRT) which was formed in acid hydrolysis and aqueous hydrolysis was investigated with LCMS study. The mass of unknown impurity was 298.4 and the mass of Imp-2 (4-(3-methylamino)-1-(thiophen-2-yl) propyl) naphthalin-1-ol) was 298 and the UV spectra of Impurity-2 was similar to that of unknown impurity. Hence, based LCMS data and UV spectra, the possible chemical name of the unknown impurity could be '2-(3-methylamino)-1-(thiophen-2-yl) propyl) naphthalin-1-ol. The proposed structure of unknown impurity was positional isomer of Impurity-2. Peak purity test performed for the Duloxetine peak using photodiode array (PDA) detector, data confirmed the purity of the peak for all the stressed samples. Assay of all stressed samples were calculated using qualified standard of Duloxetine Hydrochloride. Considering the purities from the respective chromatograms of stressed samples, mass balance (%assay + % degradents + % impurities) was calculated for each stress sample. The mass balance of stressed samples was more than 99.1%.
This clearly demonstrates that the developed UPLC method was found to be specific for Duloxetine in presence of its impurities (impurity-1, impurity-2 and impurity-3) and degradation products.
Analytical method Validation, results and discussion
The developed and optimized UPLC method was taken up for validation. The analytical method validation was carried out in accordance with ICH guidelines [7, 8] .
System Suitability Test
Duloxetine standard, impurity-1, impurity-2 and impurity-3 were spiked at 0.30% level with respect to the concentration of Duloxetine in diluent and injected for five times into UPLC system. Resolution between impurities and Duloxetine, tailing factor for impurities and Duloxetine, RSD% for the areas of impurities and Duloxetine was calculated. Good resolution was obtained between impurities and Duloxetine (Fig: 4.5.F1 ).
System suitability results were tabulated in Table 4 .5.T1. 
Precision
Assay method precision (repeatability) study was evaluated by carrying out six independent assays of Duloxetine hydrochloride test sample against qualified reference standard and RSD of six consecutive assays was 0.15% (Table 4. 
5.T2). Results showed insignificant variation
in measured response which demonstrated that the method was repeatable with RSDs below 0.2%. The precision of the related substance method was evaluated by injecting six individual preparations of Duloxetine (0.2 mg mL -1 ) spiked with 0.30% of impurity-1, impurity-2 and impurity-3 with respect to Duloxetine analyte concentration. The % RSD for area of impurity-1, impurity-2 and impurity-3 for six consecutive determinations was below 2.0% (Table 4 .5.T3).
Results showed insignificant variation in measured response which demonstrated that the related substances method was repeatable with RSDs below 2.0%. 
Limit of quantification (LOQ) and limit of detection (LOD)
LOQ and LOD were established for Duloxetine and for impurity-1, impurity-2 and impurity-3 based on signal to noise ratio (S/N) method.
Limit of quantification (LOQ)
The quantification limits were established by S/N methodology and established concentration values are reported in Table 4 .5.T5. 
Precision at Limit of quantification
The precision of the related substance method was also checked by injecting six individual preparations of impurity-1, impurity-2 and impurity-3 at their LOQ level with respect to Duloxetine analyte concentration. Results showed insignificant variation in measured responses which demonstrate that the method was repeatable at LOQ level with RSD below 2.3 % (Table 4 .5.T7). 
Accuracy at LOQ level
The recovery studies for impurity-1, impurity-2 and impurity-3 were carried out in triplicate at LOQ level of the Duloxetine target analyte concentration (200 µg mL -1 ). The percentage recovery of impurity-1, impurity-2 and impurity-3 was calculated (Table 4.5.T8). The method showed consistent and high absolute recoveries at LOQ level with mean absolute recovery ranging from 94.8 % to 98.5%. 
Linearity of the related substances method
Linearity experiments were carried out by preparing the Duloxetine sample solutions containing impurity-1, impurity-2 and impurity-3 from LOQ to 150% (i.e. LOQ, 50, 100, 125 and 150%) with respect to their specification limit 0.30% (Table 4 .5.T11).
Calibration curve was drawn by plotting average area of the impurity (impurity-1, impurity-2 and impurity-3) on the Y-axis and concentration on the X-axis (Fig: 4.5.F3 to Fig: 4.5.F5 ) which showed linear relation ship with a regression coefficient of greater than 0.998 for all impurities. Analysis of residuals indicated (Table 4.5.T12 to Table 4 .5.T14) that the residuals were normally distributed around the mean with uniform variance across all concentrations suggesting the homoscedastic nature of data. Accuracy of the assay method was established by injecting three preparations of test sample using Duloxetine hydrochloride capsules 60 mg at 50%, 100% and 150% of analyte concentration (20 µg mL -1 ). Each solution was injected trice (n=3) into UPLC system and the mean peak area of Duloxetine peak was calculated. Assay of test solution was determined against three injections (n=3) of qualified Duloxetine standard. The method showed consistent and high absolute recoveries at all three concentration (50,100 and 150%) levels with mean absolute recovery ranging from 99.6 % to 101.2% (Table 4 .5.T15). The obtained absolute recoveries were normally distributed around the mean with uniform RSD values.
Accuracy of the RS method
Accuracy of the related substances method established at 50%, 100% and 150% of the impurities specification limit (0.20%). Test solutions were prepared in triplicate (n=3) with impurities (impurity-1, impurity-2 and impurity-3) at 0.15%, 0.30% and 0.45% level w.r.t. analyte concentration (0.2 mg mL -1 ). Mean % recovery of impurities calculated in the test solution using the area of impurities standard at 0.30% level with respect to analyte (Table 4.5.T15). The related substances method showed consistent and high absolute recoveries of all five impurities at all three concentration (50,100 and 150%) levels with mean absolute recovery ranging from 93.3 % to 104.5% in drug product.
Solution state stability
The solution state stability of Duloxetine in diluent in the assay method was carried out by leaving the test solutions of sample in tightly capped volumetric flasks at room temperature for two days. The same sample solution were assayed for every 24 hours interval up to the study period, each time freshly prepared reference standard was used to estimate the assay of test sample. The % RSD of assay of Duloxetine during solution stability experiments was with in 1.0%.
The solution stability of Duloxetine in the related substance method was carried out by leaving sample solution in tightly capped volumetric flask at room temperature for two days. Content of impurity-1, impurity-2, and impurity-3 were checked for every 24 hours interval up to the study period. No significant change was observed in the impurity content during solution stability experiments from the initial values up to the study period. Hence Duloxetine sample solutions are stable for at least 48 hours in the developed method.
Mobile phase stability of the developed method was established by injecting fresh samples for 48 hours. Fresh sample solution was assayed for every 24 hours interval up to the study period, each time freshly prepared reference standard was used to estimate the assay of sample. The % RSD of assay of Duloxetine during solution stability experiments was with in 1.0. 
Robustness
To determine the robustness of the developed method experimental conditions were purposely altered and the resolution between impurity-1 and Duloxetine and between Duloxetine and impurity-2 were evaluated.
In each of the deliberately altered chromatographic condition (flow rate 0.5 mL min -1 and O.7 mL min -1 , varying column temperature from 35°C to 45 0 C), varying pH of mobile phase by −1 to +1 units), the resolution between impurity-1, Duloxetine, impurity-2 and impurity-3 was greater than 2.4 and tailing factor for Duloxetine and its impurities was less than 1.3, illustrating the good robustness of the method.
Mass balance
The stressed samples of Duloxetine hydrochloride drug product were assayed against the qualified reference standard and the results of mass balance obtained were very close to 99%. The results of mass balance obtained in each condition are presented below (Table 4 .5.T17). pharmaceutical manufacturers hope will better predict the in vivo performance of drug products. In addition, the reliability and discriminatory capabilities of dissolution methods for delayed release products has gained much attention in recent years. The most widely used dissolution tests for delayed release products use 900 or 1000 mL of an acid medium followed by 900 or 1000 mL of aqueous buffer medium with USP apparatus I (basket) or apparatus II (paddle) at rotation speeds of 100 or 50 RPM, respectively. It is desirable to have an in vitro dissolution method that is sensitive to formulation factors that affect the dissolution process and in consequence bioavailability. In our study, release characteristics of Duloxetine hydrochloride capsules were studied according to the FDA dissolution method (Basket) at 37 C ± 0.5 using 1000 mL of 0.1N HCl (2 h) followed by 1000 mL of 6.8 phosphate buffer (pH6.8) at 100 RPM rotation speed [9] . In vitro dissolution was conducted on Duloxetine hydrochloride 60 mg test product and on Duloxetine hydrochloride 60 mg innovator (Cymbalta) product. At scheduled time intervals, 1 mL of sample was withdrawn and replaced with fresh medium. The final solution was filtered through 0.45 µm nylon membrane filter and then analyzed by the proposed UPLC method.
The dissolution characteristics of Duloxetine hydrochloride are given 
Summary and Conclusions
A new reverse phase ultra performance liquid chromatographic method was developed for assay and impurities estimation Duloxetine hydrochloride with stability-indicating power for pharmaceutical dosage forms. The proposed developed method is capable of separating all Duloxetine hydrochloride impurities in presence degradation impurities formed under forced degradation studies and also proposed method can be employed for assay determination of Duloxetine hydrochloride in pharmaceutical dosage forms. The column used for development of this method was Zorbax XDB C-18, 50 mm × 4.6 mm, 1.8 µm column. The detection wavelength was to monitor eluted components was 236 nm. Duloxetine hydrochloride capsules pellets were exposed to degradation conditions of acid, oxidative, base, hydrolytic, photolytic and thermal degradation. The degradation impurities were well separated from Duloxetine peak and its related compounds, showed the stabilityindicating nature and power of the developed method. The developed UPLC method was also applied for in-vitro dissolution studies for test and innovator products. The developed method was validated as per ICH guidelines for precision, accuracy, linearity, specificity, limit of detection, limit of quantification, system suitability and robustness and found to be precise, accurate, linear rugged, robust and specific. Thus the developed and validated liquid chromatographic method can be used for stability analysis and production samples analysis of Duloxetine hydrochloride in pharmaceutical dosage forms. Robustness the resolution between Impurity-1, Duloxetine, Impurity-2 and Impurity-3 was greater than 2.4
Solution Stability
Standard and test solutions were stable for 48 hours at room temperature
Mobile phase Stability
Mobile phase was stable for 48 hours at room temperature Specificity For all stress conditions, purity angle is less than the purity threshold and there is no purity flag observed for purity results
